In a child‑bearing‑age woman with recurrent anal fistula and mild Crohn disease, should maintenance therapy with infliximab or other anti‑TNF biologics be initiated?

Yes, Maintenance Infliximab is Highly Warranted for This Patient

For a child-bearing age woman with recurrent anal fistula and mild Crohn's disease, maintenance therapy with infliximab should be initiated. This recommendation is based on strong guideline evidence specifically addressing perianal fistulizing disease, with the additional consideration that continuing biologics through pregnancy is safer than allowing disease flare.

Primary Rationale: Perianal Fistulizing Disease Drives Treatment Decisions

The presence of recurrent anal fistula fundamentally changes the treatment paradigm, even when luminal disease is mild. Current guidelines make a clear distinction:

• Infliximab is strongly recommended for induction and maintenance of fistula remission in perianal Crohn's disease (strong recommendation, moderate certainty of evidence) 1, 2
• Biologic agents should be used early in perianal disease, rather than delaying until after failure of conventional therapy (conditional recommendation, low certainty evidence) 1
• For pediatric patients with active perianal fistulizing disease, anti-TNF therapy is recommended as primary induction and maintenance therapy in combination with appropriate surgical intervention 3

The "mild" designation of luminal disease becomes secondary when perianal fistulas are present and recurrent, as fistulizing disease represents a more aggressive phenotype requiring more intensive therapy.

Evidence Supporting Maintenance Therapy

Landmark trial data demonstrates clear benefit of maintenance infliximab:

• Time to loss of response was significantly longer with infliximab maintenance versus placebo (>40 weeks vs 14 weeks, P<0.001) 4
• At 54 weeks, 36% of patients on infliximab maintenance had complete absence of draining fistulas versus 19% on placebo (P=0.009) 4
• Complete response to infliximab is associated with reduced need for surgical intervention 5

Infliximab demonstrates superior efficacy compared to adalimumab for perianal fistulas:

• At 6 months, 64.9% of infliximab-treated patients showed clinical improvement versus 34.8% with adalimumab (p<0.01) 6
• Biologic persistence was significantly longer with infliximab compared to adalimumab 6

Special Considerations for Child-Bearing Age

The patient's reproductive age is actually an additional reason to initiate and maintain biologic therapy, not a contraindication:

Continuation of anti-TNF therapy through pregnancy is strongly recommended:

• In pregnant women with IBD on anti-TNF maintenance therapy, continuation is strongly recommended (strong recommendation, very low-quality evidence) 7
• Discontinuation of anti-TNF therapy increases disease relapse risk (45.8% vs 30.6%, P=0.005) 8
• Active disease during pregnancy increases risks of preterm birth, neonatal infections, and adverse neurodevelopmental outcomes 8
• Continuation of anti-TNF therapy was associated with lower frequency of preterm birth (7.6% vs 8.9%; aRR 0.82) 8

Safety profile supports use in pregnancy:

• Available data from published literature have not reported a clear association between infliximab and adverse pregnancy outcomes 9
• Infliximab crosses the placenta, but this is manageable with appropriate neonatal precautions (avoiding live vaccines for 6 months) 9

Optimal Treatment Strategy

Infliximab should be combined with antibiotics for induction:

• Strong recommendation exists for using biologic agents in combination with antibiotics over biologic alone for induction of fistula remission (strong recommendation, moderate certainty of evidence) 1, 2

Dosing regimen:

• Standard induction: 5 mg/kg at weeks 0,2, and 6
• Maintenance: 5 mg/kg every 8 weeks 3
• Dose escalation to 10 mg/kg or shortening intervals to every 4 weeks may be required for loss of response 3

Surgical coordination:

• Ensure any perianal abscesses are drained before or concurrent with biologic initiation
• Consider seton placement for complex fistulas 1, 10

Common Pitfalls to Avoid

1. Do not delay biologic therapy waiting for conventional therapy failure in perianal disease—guidelines explicitly recommend early biologic use 1

2. Do not discontinue therapy if pregnancy is planned or occurs—continuation is safer than disease flare 7, 8

3. Do not use antibiotics alone for perianal fistulas—they are insufficient as monotherapy (strong recommendation against) 1, 2

4. Do not use corticosteroids for maintenance—they are contraindicated for maintenance of remission (strong recommendation against) 1, 2

5. Do not assume "mild" luminal disease means conservative therapy is adequate—recurrent perianal fistulas indicate need for aggressive treatment regardless of luminal severity

Monitoring and Long-Term Management

• Evaluate primary efficacy after the second or third infliximab dose 3
• Consider measuring trough levels and antibodies if partial response or loss of response occurs 3
• Pre-conception counseling should emphasize safety of continuing therapy through pregnancy
• Coordinate with high-risk obstetrics if pregnancy occurs 7
• Ensure tuberculosis screening before initiating therapy 3

The combination of recurrent perianal fistulas and child-bearing age makes infliximab maintenance therapy not just warranted, but essential for optimizing both disease control and future pregnancy outcomes.